Twist Bioscience Co. (NASDAQ:TWST) Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. boosted its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 67.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 205,864 shares of the company’s stock after purchasing an additional 82,953 shares during the period. Principal Financial Group Inc. owned approximately 0.35% of Twist Bioscience worth $9,301,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Silvercrest Asset Management Group LLC raised its stake in Twist Bioscience by 38.6% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after acquiring an additional 37,376 shares during the last quarter. Magnetar Financial LLC purchased a new position in shares of Twist Bioscience in the first quarter worth about $389,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Twist Bioscience by 7.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 32,127 shares of the company’s stock worth $1,103,000 after purchasing an additional 2,292 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in Twist Bioscience in the second quarter valued at approximately $402,000. Finally, Edgestream Partners L.P. acquired a new position in Twist Bioscience in the 1st quarter worth approximately $242,000.

Analysts Set New Price Targets

TWST has been the subject of several research reports. Barclays decreased their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Leerink Partners upped their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. increased their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. Evercore ISI upped their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Robert W. Baird lifted their price target on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and an average price target of $51.22.

Twist Bioscience Stock Performance

Shares of TWST opened at $41.43 on Tuesday. The stock has a 50 day moving average price of $43.98 and a 200 day moving average price of $46.18. The stock has a market capitalization of $2.43 billion, a price-to-earnings ratio of -10.85 and a beta of 1.78. Twist Bioscience Co. has a one year low of $23.00 and a one year high of $60.90.

Insider Activity

In related news, Director Robert Chess sold 3,600 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $47.26, for a total transaction of $170,136.00. Following the completion of the sale, the director now directly owns 21,641 shares of the company’s stock, valued at approximately $1,022,753.66. This trade represents a 14.26 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Emily M. Leproust sold 1,730 shares of the stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $46.94, for a total transaction of $81,206.20. Following the transaction, the chief executive officer now directly owns 495,523 shares of the company’s stock, valued at approximately $23,259,849.62. This trade represents a 0.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 98,118 shares of company stock worth $4,391,151 over the last three months. Insiders own 3.92% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.